![]()
|
|
||||||||
J. Biol. Chem., Vol. 283, Issue 21, 14295-14308, May 23, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

1


2
¶||23
From the
Sidney Kimmel Comprehensive Cancer Center, the ¶Department of Molecular Biology and Genetics and ||Department of Biology, The Johns Hopkins University, Baltimore, Maryland 21231 and the
Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts
Although the role of human IRF-5 in antiviral and inflammatory responses in vitro has been well characterized, much remains to be elucidated about murine IRF-5. Murine IRF-5, unlike the heavily spliced human gene, is primarily expressed as a full-length transcript, with only a single splice variant that was detected in very low levels in the bone marrow of C57BL/6J mice. This bone marrow variant contains a 288-nucleotide deletion from exons 4–6 and exhibits impaired transcriptional activity. The murine IRF-5 can be activated by both TBK1 and MyD88 to form homodimers and bind to and activate transcription of type I interferon and inflammatory cytokine genes. The importance of IRF-5 in the antiviral and inflammatory response in vivo is highlighted by marked reductions in serum levels of type I interferon and tumor necrosis factor
(TNF
) in Newcastle disease virus-infected Irf5–/– mice. IRF-5 is critical for TLR3-, TLR4-, and TLR9-dependent induction of TNF
in CD11c+ dendritic cells. In contrast, TLR9, but not TLR3/4-mediated induction of type I IFN transcription, is dependent on IRF-5 in these cells. In addition, IRF-5 regulates TNF
but not type I interferon gene transcription in Newcastle disease virus-infected peritoneal macrophages. Altogether, these data reveal the cell type-specific importance of IRF-5 in MyD88-mediated antiviral pathways and the widespread role of IRF-5 in the regulation of inflammatory cytokines.
Received for publication, January 18, 2008 , and in revised form, March 7, 2008.
* This work was supported, in whole or in part, by National Institutes of Health Grants R01 AI067632 (to P. M. P.) and AI067497 (to K. A. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Experimental Procedures, Table 1, and Figs. 1–4.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) EU_401974.
1 Present address: Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
2 Both authors contributed equally to this work.
3 To whom correspondence should be addressed: The Johns Hopkins School of Medicine, 1650 Orleans St., Baltimore, MD 21231. Tel.: 410-955-8871; Fax: 410-955-0840; E-mail: parowe{at}jhmi.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |